<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="72b2e981-03dd-465e-ad71-75395a2cc624"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use LUTRATE DEPOT safely and effectively. See full prescribing information for LUTRATE DEPOT.<br/>
         <br/>
      </content>
      <content styleCode="bold">LUTRATE<sup>Â®</sup> DEPOT (leuprolide acetate), for depot suspension</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2018</content>
   </title>
   <effectiveTime value="20250314"/>
   <setId root="3a6d1373-17d9-4289-b62f-d299ffe55831"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="128918748" root="1.3.6.1.4.1.519.1"/>
            <name>Avyxa Pharma, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2419540a-8502-4823-8d5e-30e530c8da19"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250325"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="83831-134" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>LUTRATE DEPOT</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>leuprolide acetate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="83831-134-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250326"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102842" displayName="Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="83831-150" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>LUTRATE DEPOT</name>
                              <formCode code="C42956" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASE"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>leuprolide acetate</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="22.5" unit="mg"/>
                                    <denominator value="2" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="37JNS02E7V" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEUPROLIDE ACETATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="EFY6W0M8TG" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LEUPROLIDE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="25" unit="mg"/>
                                    <denominator value="2" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="88.4" unit="mg"/>
                                    <denominator value="2" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="188.4" unit="mg"/>
                                    <denominator value="2" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="459TN2L5F5" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYLACTIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="3.8" unit="mg"/>
                                    <denominator value="2" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="10.4" unit="mg"/>
                                    <denominator value="2" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TRIETHYL CITRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="mL"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="83831-150-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43215" displayName="VIAL, SINGLE-DOSE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA205054" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250326"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="83831-135" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>DILUENT</name>
                              <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mannitol solution</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANNITOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="mL"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="83831-135-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43202" displayName="SYRINGE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102835" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA205054" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250326"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205054" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250326"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="19bb7c67-1de5-49da-95d4-cf052191d2a5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43683-2" displayName="RECENT MAJOR CHANGES SECTION"/>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Warnings and Precautions (<linkHtml href="#_5_2_Hyperglycemia_and">5.2</linkHtml>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â Â Â  12/2023</paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#L5a5ac3a7-4714-4503-9da6-8b8995e82b61">5.6</linkHtml>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  11/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="L20022dbd-7945-401a-a771-53dc3f1980ff">
               <id root="b5748bc5-c091-4fa7-897d-773ac9fdb875"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>LUTRATE DEPOT 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer.</paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>LUTRATE DEPOT is a gonadotropin-releasing hormone (GnRH) agonist indicated for:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Treatment of advanced prostate cancer. (<linkHtml href="#L20022dbd-7945-401a-a771-53dc3f1980ff">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_2_DOSAGE_AND">
               <id root="7843fea4-b600-4cbb-90d6-ac4df22fbe17"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule (<linkHtml href="#_2_DOSAGE_AND">2</linkHtml>).</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>LUTRATE DEPOTÂ 22.5 mg for 3 months administration, given as a single intramuscular injection every 12 weeks.Â (<linkHtml href="#L04648459-b708-4f1d-af99-a86ea0fe96b4">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="L04648459-b708-4f1d-af99-a86ea0fe96b4">
                     <id root="bd3f3907-4f71-4f6b-a374-cd5d67327197"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 LUTRATE DEPOT 22.5 mg for 3-Month Administration</title>
                     <text>
                        <paragraph>LUTRATE DEPOTÂ must be administered under the supervision of a physician.</paragraph>
                        <paragraph>In patients treated with GnRH analogues for prostate cancer, treatment is usually continued upon development of metastatic castration-resistant prostate cancer.</paragraph>
                        <table>
                           <caption>Table 1.Â LUTRATE DEPOT Recommended Dosing</caption>
                           <colgroup>
                              <col width="50%"/>
                              <col width="50%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" align="left">Dosage</td>
                                 <td styleCode="Lrule Rrule Toprule" align="left">22.5 mg for 3-Month Administration</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" align="left">Recommended Dose</td>
                                 <td styleCode="Lrule Rrule Toprule" align="left">1 injection every 12 weeks</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The recommended dose of LUTRATE DEPOT 22.5 mg for 3-month administration is one injection every 12 weeks. Do not use concurrently a fractional dose, or a combination of doses of this or any depot formulation due to different release characteristics.</paragraph>
                        <paragraph>Incorporated in a depot formulation, the lyophilized microspheres must be reconstituted and administered every 12 weeks as a single intramuscular injection.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="L4d47daf2-8d7f-4292-b198-5bfd8b2d2e71">
                     <id root="2c26df3a-caeb-4ed5-9e05-7b6b340addef"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Reconstitution Instructions forÂ LUTRATE DEPOT</title>
                     <text>
                        <list listType="unordered">
                           <item>Reconstitute and administer the lyophilized microspheres as a single intramuscular injection.</item>
                           <item>The suspension should be administered immediately after reconstitution.</item>
                           <item>As with other drugs administered by intramuscular injection, the injection site should be alternated periodically.</item>
                           <item>Visually inspect LUTRATE DEPOT powder (white to off-white powder). DO NOT USE the vial if clumping or caking is evident. A thin layer of powder on the wall of the vial is considered normal prior to mixing with the diluent. The diluent contained in the prefilled syringe should appear clear and colorless.</item>
                           <item>Use ONLY the provided diluent for reconstitution of LUTRATE DEPOT. DO NOT use other diluents.</item>
                           <item>The reconstituted product is a suspension of milky, white color appearance.</item>
                        </list>
                        <paragraph>LUTRATE DEPOT is packaged in a commercial kit. Each kit contains:</paragraph>
                        <list listType="unordered">
                           <item>One vial containing 22.5 mg of leuprolide acetate as lyophilized microspheres.</item>
                           <item>One prefilled syringe containing 2 mL of mannitol for injection.</item>
                           <item>One MIXJECT transfer device including one needle.</item>
                        </list>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lbbfad6c1-2c04-4b27-a834-dfe61dcd428b"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="bold">Please read the instructions completely before you begin.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">MIXJECT Preparation</content>
                        </paragraph>
                        <paragraph>Wash your hands with soap and hot water and put on gloves<sup>1</sup>Â immediately prior to preparing the injection. Place the tray on a clean, flat surface that is covered with a sterile pad or cloth. Remove the MIXJECT device, the backstop, the prefilled syringe containing the solvent for reconstitution and the LUTRATE DEPOTÂ vial.</paragraph>
                        <paragraph>Remove the Flip-Off button from the top of the vial, revealing the rubber stopper. Place the vial in a standing upright position on the prepared surface. Disinfect the rubber stopper with the alcohol wipe. Discard the alcohol wipe and allow the stopper to dry.Â <content styleCode="italics">
                              <content styleCode="bold">Insert the backstop to the flange of the syringe until you feel it snap in place</content>
                           </content>.Â Proceed to MIXJECT Activation.</paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="L88663107-637f-4ec6-8783-6a4b9758820e"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">MIXJECT Activation</content>
                        </paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Peel the cover away from the blister pack containing the vial adapter (MIXJECT).<content styleCode="italics">
                                 <content styleCode="bold">Â Do not remove the vial adapter from the blister pack.Â </content>Place the blister</content> pack containing the vial adapter firmly on the vial top, piercing the vial.Â <content styleCode="italics">
                                 <content styleCode="bold">Push down gently until you feel it snap in place.</content>
                              </content>
                              <table>
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="L18a904d2-4ae5-4ad7-b862-4ca318b8e6b0"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>Remove the cap from the syringe barrel and then,Â <content styleCode="italics">
                                 <content styleCode="bold">remove the blister pack from the vial adapter</content>
                              </content>.Â Connect the syringe to the vial adapter by screwing it clockwise into the opening on the side of the vial adapter. Be sure to gently twist the syringe until it stops turning to ensure a tight connection.<br/>
                              <table>
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="L6a3511e1-9a66-48b7-8925-6547bf0e8926"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>While holding the vial, place your thumb on the plunger rod and push the plunger rod in all the way to transfer the diluent from the pre-filled syringe into the vial. Do not release the plunger rod.<br/>
                              <table width="100%">
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="L7ef4ce32-8677-433a-8af6-feef8b7616e6"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>
                              <content styleCode="italics">
                                 <content styleCode="bold">Keeping the plunger rod depressed, gently swirl the vial for approximately one minute until a uniform milky-white suspension is obtained</content>
                              </content>.Â This will ensure complete mixing of LUTRATE DEPOT and the sterile mannitol solution diluent. The suspension will now have a milky appearance. In order to avoid separation of the suspension, proceed to the next steps without delay.<br/>
                              <table width="100%">
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="Lb60012dc-9ce7-4c96-8114-89707fe1c16b"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>Invert the MIXJECT system so that the vial is at the top. Grasp the MIXJECT system firmly by the syringe and pull back the plunger rod slowly to draw the reconstituted LUTRATE DEPOT into the syringe.<br/>
                              <table width="100%">
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="L092d6d07-bd99-406e-a105-abc807de5f1a"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>Return the vial to its upright position, and disconnect the vial adapter from the MIXJECT syringe assembly by grabbing firmly the syringe and turning the plastic cap of the vial adapter clockwise.Â <content styleCode="italics">
                                 <content styleCode="bold">Grasp only the plastic cap when removing</content>
                              </content>.<br/>
                              <table>
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="Lb365e2f1-ac20-4bf2-8833-d335267852a9"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>Keep the syringe UPRIGHT. With the opposite hand pull the needle cap upward. Advance the plunger to expel the air from the syringe. The syringe containing LUTRATE DEPOTÂ is now ready for administration.Â <content styleCode="italics">The suspension should be administered immediately after reconstitution.</content>
                              <br/>
                              <table>
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                          <renderMultiMedia referencedObject="Labd678bb-28db-4d44-a47f-173edc34b62e"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>After cleaning the injection site with an alcohol swab, administer the intramuscular injection by inserting the needle at a 90 degree angle into the gluteal area, anterior thigh, or deltoid; injection sites should be alternated (see Figure).<br/>
                              <table>
                                 <colgroup>
                                    <col width="100%" align="center" valign="top"/>
                                 </colgroup>
                                 <tbody>
                                    <tr styleCode="First Last">
                                       <td styleCode="Botrule Lrule Rrule Toprule" align="center">
                                          <renderMultiMedia referencedObject="Led7643cc-ad39-4786-9fce-1bf9d150b025"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>NOTE: If a blood vessel is accidentally penetrated, aspirated blood will be visible just below the luer lock. If blood is present, remove the needle immediately. Do not inject the medication.</item>
                           <item>Inject the entire contents of the syringe intramuscularly.</item>
                           <item>Withdraw the needle. Once the syringe has been withdrawn, immediately discard the needle into a suitable sharps container. Dispose the syringe according to local regulations/procedures.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241101"/>
                     <component>
                        <observationMedia ID="Lbbfad6c1-2c04-4b27-a834-dfe61dcd428b">
                           <text>fig 1.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L88663107-637f-4ec6-8783-6a4b9758820e">
                           <text>fig 2.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L18a904d2-4ae5-4ad7-b862-4ca318b8e6b0">
                           <text>Fig 3.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L6a3511e1-9a66-48b7-8925-6547bf0e8926">
                           <text>fig 4.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L7ef4ce32-8677-433a-8af6-feef8b7616e6">
                           <text>fig 5.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Lb60012dc-9ce7-4c96-8114-89707fe1c16b">
                           <text>ifig 6.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure06.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="L092d6d07-bd99-406e-a105-abc807de5f1a">
                           <text>fig 7.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure07.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Lb365e2f1-ac20-4bf2-8833-d335267852a9">
                           <text>fig 8.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure08.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Labd678bb-28db-4d44-a47f-173edc34b62e">
                           <text>fig 9.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure09.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="Led7643cc-ad39-4786-9fce-1bf9d150b025">
                           <text>fig 10.jpg</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure010.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="7cbf1304-c37a-4c3a-91ab-98b6a1802e1d"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>LUTRATE DEPOT</paragraph>
                  <paragraph>For Injection: 22.5 mg of leuprolide acetate for 3-month administration as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe containing 2mL 0.8% mannitol solution and a MIXJECT transfer device for a single dose injection.</paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For Injection: 22.5 mg of leuprolide acetate in a single dose vial as a kit with a prefilled syringe containing diluent and a MIXJECT transfer device. (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="88ff8988-c6ef-49ef-a1ac-4cbdb4cf027a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">LUTRATE DEPOT is contraindicated in:</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">Hypersensitivity</content>
                        <br/> LUTRATE DEPOT is contraindicated in individuals with known hypersensitivity to GnRH agonists or any of the excipients in LUTRATE DEPOT. Reports of anaphylactic reactions to GnRH agonists have been reported in the medical literature.</item>
                  </list>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hypersensitivity to GnRH, GnRH agonist or any of the excipients in LUTRATE DEPOT. (<linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="5cef46bc-98c8-4043-afd4-4a2d82950308"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Tumor Flare: Increased serum testosterone (~50% above baseline) during first week of treatment; monitor serum testosterone and PSA. (<linkHtml href="#_5_6_Laboratory_Tests">5.7</linkHtml>)<list listType="unordered" styleCode="Circle">
                                 <item>Transient worsening of symptoms, or additional signs and symptoms of prostate cancer during the first few weeks of treatment. (<linkHtml href="#_5_1_Tumor_Flare">5.1</linkHtml>)</item>
                                 <item>Patients may experience a temporary increase in bone pain which can be managed symptomatically. (<linkHtml href="#_5_1_Tumor_Flare">5.1</linkHtml>)</item>
                                 <item>Ureteral obstruction and spinal cord compression have been reported with GnRH agonists, which may contribute to paralysis with or without fatal complications. (<linkHtml href="#_5_1_Tumor_Flare">5.1</linkHtml>)</item>
                              </list>
                           </item>
                           <item>Metabolic Syndrome: The use of GnRH agonists may lead to an increased risk of metabolic changes such as hyperglycemia, diabetes, hyperlipidemia,Â and non-alcoholic fatty liver disease. Monitor for signs and symptoms of metabolic syndrome including lipids, blood glucose level and/or HbA1c and manage according to current treatment guidelines. (<linkHtml href="#_5_2_Hyperglycemia_and">5.2</linkHtml>)</item>
                           <item>Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH analogs in men. Monitor for cardiovascular disease and manage according to current clinical practice.Â (<linkHtml href="#_5_3_Cardiovascular_Diseases">5.3</linkHtml>)</item>
                           <item>Effect on QT/QTc Interval: Androgen deprivation therapy may prolong QT interval. Consider risks and benefits. (<linkHtml href="#_5_4_Effect_on">5.4</linkHtml>)</item>
                           <item>Convulsions have been observed in patients with or without a history of predisposing factors. Manage convulsions according to the current clinical practice.Â (<linkHtml href="#_5_5_Convulsions">5.5</linkHtml>)</item>
                           <item>Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), may occur in patients treated with LUTRATE DEPOT. InterruptÂ LUTRATE DEPOT if signs or symptoms of SCARs develop. Permanently discontinue if SCARs are confirmed. (<linkHtml href="#L5a5ac3a7-4714-4503-9da6-8b8995e82b61">5.6</linkHtml>)</item>
                           <item>Monitor serum levels of testosterone following injection of LUTRATE DEPOT 22.5 mg for 3-month administration.Â (<linkHtml href="#_5_6_Laboratory_Tests">5.7</linkHtml>)</item>
                           <item>Embryo-Fetal Toxicity: LUTRATE DEPOT may cause fetal harm. (<linkHtml href="#_5_7_Embryo_Fetal_Toxicity">5.8</linkHtml>,Â <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Tumor_Flare">
                     <id root="52a1560b-0961-438f-8cff-7f6e36dd6de7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Tumor Flare</title>
                     <text>
                        <paragraph>Initially, LUTRATE DEPOT, like other GnRH agonists, causes increases in serum levels of testosterone to approximately 50% above baseline during the first weeks of treatment. Ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications. Transient worsening of symptoms may develop. Patients may experience a temporary increase in bone pain, which can be managed symptomatically.</paragraph>
                        <paragraph>Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Hyperglycemia_and">
                     <id root="73912fd9-b0af-46a0-9456-544497ce8608"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Metabolic Syndrome</title>
                     <text>
                        <paragraph>The use of GnRH agonists may lead to metabolic changes such as hyperglycemia, diabetes mellitus, and hyperlipidemia. Non-alcoholic fatty liver disease, including cirrhosis, occurred in the post-marketing setting. Hyperglycemia may represent new-onset diabetes mellitus or worsening of glycemic control in patients with pre-existing diabetes. Monitor for changes in serum lipids, blood glucose and/or glycosylated hemoglobin (HbA1c) in patients receiving a GnRH agonist, and manage according to current treatment guidelines.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Cardiovascular_Diseases">
                     <id root="3b5b6a2c-18a4-42fe-ba15-f6e9301df6c5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cardiovascular Diseases</title>
                     <text>
                        <paragraph>Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4_Effect_on">
                     <id root="43954637-a4a0-4806-aeeb-c48d6779c14f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Effect on QT/QTc Interval</title>
                     <text>
                        <paragraph>Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5_Convulsions">
                     <id root="6dc5cafe-8aa1-48a3-a4f1-a924e48b2ec2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Convulsions</title>
                     <text>
                        <paragraph>Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above. Patients receiving a GnRH agonist who experience convulsion should be managed according to current clinical practice.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="L5a5ac3a7-4714-4503-9da6-8b8995e82b61">
                     <id root="f60927ae-d389-43f3-8a9a-69fc4e8bda27"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Severe Cutaneous Adverse Reactions</title>
                     <text>
                        <paragraph>Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), may occur in patients receiving LUTRATE DEPOT; including cases with visceral involvement and/or requiring skin grafts <content styleCode="italics">[see <linkHtml href="#_6_2_LUPRON_DEPOT">Adverse Reactions (6.2)</linkHtml>]</content>
                           <content styleCode="xmChange">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor patients for the development of SCARs. Advise patients of the signs and symptoms of SCARs (e.g., a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">If a SCAR is suspected, interruptÂ LUTRATE DEPOT until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, or for other grade 4 skin reactions, permanently discontinue LUTRATE DEPOT.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_6_Laboratory_Tests">
                     <id root="5d70a260-29c7-47de-95ff-774ec756bcad"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Laboratory Tests</title>
                     <text>
                        <paragraph>Monitor serum levels of testosterone following injection of LUTRATE DEPOT 22.5 mg for 3-month administration. In the majority of patients, testosterone levels increased above baseline during the first week, and then declined thereafter to castrate levels (&lt; 50 ng/dL) within four weeks. <content styleCode="italics">[</content>
                           <content styleCode="italics">see <linkHtml href="#_14_CLINICAL_STUDIES">Clinical Studies (14)</linkHtml> and <linkHtml href="#_6_ADVERSE_REACTIONS">Adverse Reactions (6)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_7_Embryo_Fetal_Toxicity">
                     <id root="c24aa080-98e7-4ae4-a021-ce8a4b5bd472"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on findings in animal studies, LUTRATE DEPOT may cause fetal harm when administered to a pregnant woman. In animal developmental and reproductive toxicology studies, administration of the monthly formulation of leuprolide acetate on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose, based on body surface area, using an estimated daily dose. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus <content styleCode="italics">[see <linkHtml href="#_8_1_Pregnancy">Use in Specific Populations (8.1)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6_ADVERSE_REACTIONS">
               <id root="0251c9cb-7979-4835-8a0d-4ff027b4467f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following is discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered">
                     <item>Tumor Flare <content styleCode="italics">[see <linkHtml href="#_5_1_Tumor_Flare">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Metabolic Syndrome <content styleCode="italics">[</content>
                        <content styleCode="italics">see <linkHtml href="#_5_2_Hyperglycemia_and">Warnings and Precautions (5.2)</linkHtml>
                        </content>
                        <content styleCode="italics">]</content>
                     </item>
                     <item>Cardiovascular Disease <content styleCode="italics">[see <linkHtml href="#_5_3_Cardiovascular_Diseases">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Effect on QT/QTc Interval <content styleCode="italics">[</content>
                        <content styleCode="italics">see <linkHtml href="#_5_4_Effect_on">Warnings and Precautions (5</linkHtml>
                           <linkHtml href="#_5_4_Effect_on">.4)</linkHtml>]</content>
                     </item>
                     <item>Convulsions <content styleCode="italics">[see <linkHtml href="#_5_5_Convulsions">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Severe Cutaneous Adverse Reactions<content styleCode="italics"> [see <linkHtml href="#L5a5ac3a7-4714-4503-9da6-8b8995e82b61">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt; 10%) are hot flushes, upper respiratory infection, fatigue, diarrhea, pollakiuria, arthralgia, and injection site pain (<linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>)<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph/>
                        <paragraph>As with other GnRH agonist, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy may occur. (<linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>)</paragraph>
                        <paragraph/>
                        <paragraph>
                           <br/>
                           <content styleCode="bold"> To report SUSPECTED ADVERSE REACTIONS, contactÂ Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or<content styleCode="italics"> www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_LUPRON_DEPOT">
                     <id root="ea15e28f-4f4c-4727-bcf3-e2fa881d0799"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="bold">LUTRATE DEPOTÂ 22.5 mg for 3-Month Administration</content>
                        </paragraph>
                        <paragraph>In a clinical trial of LUTRATE DEPOT 22.5 mg for 3-month administration, patients were treated for 24 weeks with 157/163 receiving two injections. The table includes adverse reactions were reported in 5% or more of the patients during the treatment period as well as the incidence of these adverse reaction that were considered, by the treating physician, to be at least possibly related to LUTRATE DEPOT. Grade 3-4 adverse reactions reported as treatment-emergent in 13% of patients and treatment-related 4% of patients.</paragraph>
                        <table>
                           <colgroup>
                              <col width="40%"/>
                              <col width="30%"/>
                              <col width="30%"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td styleCode="Footnote" colspan="3" align="left">
                                    <paragraph>CTCAE v.3</paragraph>
                                    <paragraph>
                                       <sup>1</sup>
                                       <content>Includes cold sweat, flushing, hot flush, hyperhidrosis, and night sweats</content>
                                    </paragraph>
                                    <sup>2</sup>Includes influenza, influenza-like illness, nasal congestion, nasopharyngitis, rhinorrhea, upper respiratory tract infection and congestion</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">
                                    <content styleCode="bold">Table 2. Adverse Reactions Reported in â¥ 5% of Patients</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule" colspan="3" align="center">
                                    <content styleCode="bold">LUTRATE DEPOT 22.5 mg for 3-Month Administration</content>
                                    <paragraph>
                                       <content styleCode="bold">N = 163 (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"/>
                                 <td styleCode="Lrule Rrule Toprule" colspan="2" align="center">
                                    <content styleCode="bold">Grade 1-4</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"/>
                                 <td styleCode="Lrule Rrule Toprule" align="center">Treatment-Emergent</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">Treatment-Related</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Hot Flush/Flushing<sup>1</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">128 (79)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">127 (78)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Upper Respiratory Infection<sup>2</sup>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">28 (17)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Fatigue/Asthenia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">24 (15)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">22 (13)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Diarrhea</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">21 (13)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2 (1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Pollakiuria</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">20 (12)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">3 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Arthralgia/Arthritis</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18 (11)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2 (1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Injection Site Pain/Discomfort</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">18 (11)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">15 (9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Constipation</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">15 (9)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1 (0.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Extremity Pain</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14 (9)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Nausea</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14 (9)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Nocturia</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">14 (9)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">3 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Abdominal Pain/Discomfort</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13 (8)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1 (0.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Urinary Tract Pain</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">13 (8)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2 (1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Dizziness</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12 (7)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">2 (1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Headache/Sinus Headache</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12 (7)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1 (0.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Urinary Tract Infection</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">12 (7)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Bone Pain</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">11 (7)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">4 (2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Back Pain</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10 (6)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">1 (0.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Hypertension/Blood Pressure Increased</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">10 (6)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">Pruritus/Generalized Pruritus</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">9 (6)</td>
                                 <td styleCode="Lrule Rrule Toprule" align="center">3 (2)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the same study, erectile dysfunction and testicular atrophy were reported in patients on LUTRATE DEPOT 22.5 mg.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Laboratory abnormalities</content>
                        </paragraph>
                        <paragraph>During the treatment period, at least a one grade change in laboratory values was seen (&gt;10%) in the following: anemia, increased triglyceride, hyperglycemia, increased cholesterol, increased creatine kinase, leukopenia, increased AST, increased creatinine, and increased ALT.</paragraph>
                     </text>
                     <effectiveTime value="20250207"/>
                  </section>
               </component>
               <component>
                  <section ID="_6_2_LUPRON_DEPOT">
                     <id root="e9885bba-017c-42d0-a9c6-b49130c54bfb"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-marketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post approval use of gonadotropin-releasing hormone agonists. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Mood swings, including depression, have been reported. There have been very rare reports of suicidal ideation and attempt. Many, but not all, of these patients had a history of depression or other psychiatric illness. Patients should be counseled on the possibility of development or worsening of depression during treatment with LUTRATE DEPOT.</paragraph>
                        <paragraph>Symptoms consistent with an anaphylactoid or asthmatic process have been rarely (incidence rate of about 0.002%) reported. Rash, urticaria, and photosensitivity reactions have also been reported.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pituitary apoplexy:</content> During postmarketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.</paragraph>
                        <paragraph>Localized reactions including induration and abscess have been reported at the site of injection.</paragraph>
                        <paragraph>Symptoms consistent with fibromyalgia (e.g., joint and muscle pain, headaches, sleep disorders, gastrointestinal distress, and shortness of breath) have been reported individually and collectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Changes in Bone Density:</content> Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with a GnRH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of pain. The leuprolide acetate-treated group had lower bone density scores than the nontreated control group. It can be anticipated that long periods of medical castration in men will have effects on bone density.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Immune Disorders:</content> Anaphylaxis</paragraph>
                        <paragraph>
                           <content styleCode="underline">Psychiatric Disorders:</content> Depression</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiovascular System</content> - hypotension, myocardial infarction, pulmonary embolism</paragraph>
                        <paragraph>
                           <content styleCode="underline">Respiratory, Thoracic and Mediastinal disorder</content> - Pneumonitis, interstitial lung disease</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hepato-biliary disorder </content>- serious drug-induced liver injury, non-alcoholic fatty liver disease</paragraph>
                        <paragraph>
                           <content styleCode="underline">Skin reactions</content> â rash, urticaria, photosensitivity, erythema multiforme, bullous dermatitis, exfoliative dermatitis, DRESS, SJS/TEN, and AGEP</paragraph>
                        <paragraph>
                           <content styleCode="underline">Blood and Lymphatic System</content> - decreased WBC</paragraph>
                        <paragraph>
                           <content styleCode="underline">Central/Peripheral Nervous System</content> - convulsion, peripheral neuropathy, spinal fracture/paralysis</paragraph>
                        <paragraph>
                           <content styleCode="underline">Endocrine System</content> - diabetes mellitus</paragraph>
                        <paragraph>
                           <content styleCode="underline">Musculoskeletal System</content> - tenosynovitis-like symptoms</paragraph>
                        <paragraph>
                           <content styleCode="underline">Urogenital System</content> - prostate pain</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="17fe42f9-8e7d-48db-acc4-3a791b5833e1"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text>
                  <paragraph>No pharmacokinetic-based drug-drug interaction studies have been conducted with LUTRATE DEPOT.</paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <component>
                  <section>
                     <id root="0763603a-08f3-42a2-8a53-bff963d76cbf"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34074-5" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>7.1 Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Administration of LUTRATE DEPOT in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within three months after treatment is discontinued. Due to the suppression of the pituitary-gonadal system by LUTRATE DEPOT, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment and up to three months after discontinuation of LUTRATE DEPOT may be affected.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7679de17-3751-4c47-a09e-2dd5a063461a"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20241101"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Females and males of reproductive potential: LUTRATE DEPOT may impair fertility. Counsel patients on pregnancy planning and prevention. (<linkHtml href="#_8_3_Females_and">8.3</linkHtml>)</item>
                           <item>Pediatric: The use of LUTRATE DEPOT formulations are not indicated for use in children (<linkHtml href="#_8_4_PEDIATRIC_USE">8.4</linkHtml>)</item>
                           <item>Geriatric: This label reflects clinical trials for LUTRATE DEPOT in prostate cancer in which the majority of the subjects studied were at least 65 years of age. (<linkHtml href="#_8_5_GERIATRIC_USE">8.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1_Pregnancy">
                     <id root="b6ca2ef9-a9d9-4147-b9e9-ca0073d10fe0"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Risk summary</content>
                        </paragraph>
                        <paragraph>Based on findings in animal studies and mechanism of action, LUTRATE DEPOT may cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#_12_1_Mechanism_of">Clinical Pharmacology (12.1)</linkHtml>]</content>. There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide acetate on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose <content styleCode="italics">(see data)</content>. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Major fetal malformations were observed in developmental and reproductive toxicology studies in rabbits after a single administration of the monthly formulation of leuprolide acetate on day 6 of pregnancy at doses of 0.00024, 0.0024, and 0.024 mg/kg (approximately 1/1600 to 1/16 the human dose based on body surface area using an estimated daily dose in animals and humans). Since a depot formulation was utilized in the study, a sustained exposure to leuprolide acetate was expected throughout the period of organogenesis and to the end of gestation. Similar studies in rats did not demonstrate an increase in fetal malformations, however, there was increased fetal mortality and decreased fetal weights with the two higher doses of the monthly formulation of leuprolide acetate in rabbits and with the highest dose (0.024 mg/kg) in rats.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4662203e-7e90-41b7-83b0-cb95e4f6b3d5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>The safety and efficacy of LUTRATE DEPOT have not been established in females. There is no information regarding the presence of LUTRATE DEPOT in human milk, the effects on the breastfed child, or the effects on milk production. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in a breastfed child from LUTRATE DEPOT, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_3_Females_and">
                     <id root="9485c0de-0ef7-4445-8827-382e1814d226"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77291-3" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Infertility</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Based on findings in animals and mechanism of action, LUTRATE DEPOT may impair fertility in males of reproductive potential <content styleCode="italics">[see <linkHtml href="#_13_1_Carcinogenesis__Mutagenesis_">Nonclinical Toxicology (13.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_4_PEDIATRIC_USE">
                     <id root="eca79788-84a6-4741-a3cc-e2d1bb2761e4"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of LUTRATE DEPOT in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_5_GERIATRIC_USE">
                     <id root="9bf3d195-bf67-4ae1-bf6f-c035e96fed6e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In the clinical trials for LUTRATE DEPOT in prostate cancer 74% of the patients studied were at least 65 years of age. Hot flushes occurred with equal frequency in those less than or at least 65 years of age.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="67477d34-b99a-4089-a1de-314c9d8cd867"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>There is no experience of overdosage in clinical trials. In rats, a single subcutaneous dose of 100 mg/kg (approximately 4,000 times the estimated daily human dose based on body surface area), resulted in dyspnea, decreased activity, and excessive scratching.</paragraph>
                  <paragraph>In early clinical trials with daily subcutaneous leuprolide acetate, doses as high as 20 mg/day for up two years caused no adverse effects differing from those observed with the 1 mg/day dose.</paragraph>
               </text>
               <effectiveTime value="20241101"/>
            </section>
         </component>
         <component>
            <section>
               <id root="5d684377-87fb-40ee-8bd8-9931b1df6f40"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L6a54d429-f345-4a22-8463-2b988e81dee0"/>
                  </paragraph>
                  <paragraph>Where: n=1 or 2</paragraph>
                  <paragraph>Leuprolide acetate has a molecular weight of 1209.41 as "free baseâ. Leuprolide is freely soluble in water.</paragraph>
                  <paragraph>LUTRATE DEPOTÂ 22.5 mg for 3-month administration is available in a vial containing white to off white sterile lyophilized microspheres together with the corresponding sterile reconstitution diluent in a pre-filled syringe. When LUTRATE DEPOT and the diluent are mixed together they become a suspension intended as an intramuscular injection to be given<content styleCode="bold"> ONCE EVERY 12 WEEKS</content> as a single dose.</paragraph>
                  <paragraph>Each vial of LUTRATE DEPOTÂ 22.5 mg for 3-month administration delivers leuprolide acetate (22.5 mg), polylactic acid (188.4 mg), triethylcitrate (10.4 mg), polysorbate 80 (3.8 mg), mannitol (88.4 mg) and carmellose sodium (25 mg). The prefilled syringe containing the clear reconstitution diluent (2 mL) contains mannitol (16 mg), water for injection, and sodium hydroxide and hydrochloric acid to control pH.</paragraph>
                  <paragraph>LUTRATE DEPOT is an extended release sterile, single dose injection in suspension form for intramuscular administration.</paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <component>
                  <observationMedia ID="L6a54d429-f345-4a22-8463-2b988e81dee0">
                     <text>Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1e1bd8d0-0af4-4c7c-97ca-c75d910898fa"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241101"/>
               <component>
                  <section ID="_12_1_Mechanism_of">
                     <id root="d4a4b057-34cd-4953-a3eb-f569c0854b2d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Leuprolide acetate, a GnRH agonist, acts as an inhibitor of gonadotropin secretion. Animal studies indicate that following an initial stimulation, continuous administration of leuprolide acetate results in suppression of ovarian and testicular steroidogenesis. This effect was reversible upon discontinuation of drug therapy.</paragraph>
                        <paragraph>Administration of leuprolide acetate has resulted in inhibition of the growth of certain hormone dependent tumors (prostate tumors in Noble and Dunning male rats and DMBA-induced mammary tumors in female rats) as well as atrophy of the reproductive organs.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="5e2a203b-02e7-4ed0-8146-72994d301b43"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In humans, administration of leuprolide acetate results in an initial increase in circulating levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids (testosterone and dihydrotestosterone in males, and estrone and estradiol in premenopausal females). However, continuous administration of leuprolide acetate results in decreased levels of LH and FSH. In males, testosterone is reduced to below castrate threshold. In premenopausal females, estrogens are reduced to postmenopausal concentrations. These decreases occur within two to four weeks after initiation of treatment. Long-term studies have shown that continuation of therapy with leuprolide acetate maintains testosterone below the castrate level for more than five years.</paragraph>
                        <paragraph>Leuprolide acetate is not active when given orally.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="369030c9-2199-43ed-babb-9ca1df8d9626"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Absorption</content>
                        </paragraph>
                        <paragraph>Following two sequential injections of LUTRATE DEPOT 22.5 mg administered with a 3-month interval, plasma leuprolide acetateÂ  concentrations were similar among both cycles. After first administration, mean plasma leuprolide concentration of 46.8 ng/mL was observed at approximately 2 hours and the mean concentration then declined until next injection.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distribution</content>
                        </paragraph>
                        <paragraph>The mean steady-state volume of distribution of leuprolide acetate following intravenous bolus administration to healthy male volunteers was 27 L. <content styleCode="italics">In vitro</content> binding to human plasma proteins ranged from 43% to 49%.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Elimination</content>
                        </paragraph>
                        <paragraph>The mean systemic clearance of leuprolideÂ acetate following intravenous bolus administration to healthy male volunteers was 7.6 L/h, and terminal elimination half-life was approximately 3 hours based on a two-compartment model.</paragraph>
                        <paragraph>Upon administration with different leuprolide acetate formulations, the major metabolite of leuprolide acetate is a pentapeptide (M- 1) metabolite.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="16d21430-5de9-4e4b-9a47-112d27f11215"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241101"/>
               <component>
                  <section ID="_13_1_Carcinogenesis__Mutagenesis_">
                     <id root="527ed6f4-2f14-4eeb-91ab-916d00b0ac36"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Two-year carcinogenicity studies were conducted with leuprolide acetate in rats and mice. In rats, a dose-related increase of benign pituitary hyperplasia and benign pituitary adenomas was noted at 24 months when the drug was administered subcutaneously at high daily doses (0.6 to 4 mg/kg). There was a significant but not dose-related increase of pancreatic islet cell adenomas in females and of testicular interstitial cell adenomas in males (highest incidence in the low dose group). In mice, no leuprolide acetate-induced tumors or pituitary abnormalities were observed at a dose as high as 60 mg/kg for two years. Patients have been treated with leuprolide acetate for up to three years with doses as high as 10 mg/day and for two years with doses as high as 20 mg/day without demonstrable pituitary abnormalities. No carcinogenicity studies have been conducted with LUTRATE DEPOT.</paragraph>
                        <paragraph>Genotoxicity studies were conducted with leuprolide acetate using bacterial and mammalian systems. These studies provided no evidence of mutagenic effects or chromosomal aberrations.</paragraph>
                        <paragraph>Leuprolide acetate may reduce male and female fertility. Administration of leuprolide acetate to male and female rats at dose of 0.024, 0.24, and 2.4 mg/kg as monthly depot formulation for up to 3 months (approximately as low as 1/30 of the human dose based on body surface area using an estimated daily dose in animals and humans) caused atrophy of the reproductive organs, and suppression of reproductive function. These changes were reversible upon cessation of treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_14_CLINICAL_STUDIES">
               <id root="470b8978-219a-4118-b573-6caaf6341abd"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20241101"/>
               <component>
                  <section>
                     <id root="5de4ccf0-5b29-4334-bdce-2a225a538363"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 LUTRATE DEPOT 22.5 mg for 3-Month Administration</title>
                     <text>
                        <paragraph>The efficacy of LUTRATE DEPOT 22.5 mg was evaluated in an open-label, multicenter, non-controlled, multiple dose clinical trial which enrolled 162 evaluable patients with prostate cancer. Patients were administered LUTRATE DEPOT 22.5 mg intramuscularly in 2 doses (157 received 2 injections) with a 3-month interval.</paragraph>
                        <paragraph>The median age was 71 years (range; 47-91), 62% White, and 30% Black or African-American.</paragraph>
                        <paragraph>Castrate levels of serum testosterone (&lt;50 ng/dL) were achieved and maintained from Day 28 to 168 in 94.3% (95% CI:89.4, 97.0) of patients. On Day 28, 160 of the 162 (98.8%) patients had castrate testosterone levels. One patient did not achieve a castrate level and one had a missing value. Testosterone escapes (any value &gt; 50 ng/dL after castrate levels were achieved) occurred in four patients. In addition, three patients had a single unevaluable testosterone level after Day 28 that was considered to be non-castrate in this analysis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Mean testosterone plasma levels during treatment with two three-month IM injections of LUTRATE DEPOT 22.5 mg</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia referencedObject="Lc35f5d77-235b-4ce6-a79d-25cc57bcb5ff"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241101"/>
                     <component>
                        <observationMedia ID="Lc35f5d77-235b-4ce6-a79d-25cc57bcb5ff">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="figure1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="fa913d4f-a94a-4d6e-ac11-50eb2b875239"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34093-5" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. âOSHA Hazardous Drugs.â <content styleCode="italics">OSHA.</content>
                     <content styleCode="italics"> http://www.osha.gov/SLTC/hazardousdrugs/index.html</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241101"/>
            </section>
         </component>
         <component>
            <section>
               <id root="72c4869c-121d-48de-b829-fdb53f9d56a9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>LUTRATE<sup>Â®</sup> DEPOTÂ is supplied as a kit consisting of aÂ LEUPROLIDE ACETATE MIXJECT single-dose delivery system consisting of a vial with a Flip-Off seal containing sterile, white to off white lyophilized leuprolide acetate microspheres incorporated in a biodegradable polymer, a MIXJECT vial adapter containing the needle, and a pre-filled syringe containing clear sterile mannitol solution for injection, USP, 2 mL, pH 4.5 to 7.0.</paragraph>
                  <paragraph>LUTRATE<sup>Â®</sup> DEPOT (leuprolide acetate for depot suspension)Â 22.5 mg â NDC 83831-134-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at controlled room temperature at 20Â°-25Â°C (68Â°-77Â°F); excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F) [<content styleCode="italics">see USP Controlled Room Temperature</content>].</paragraph>
               </text>
               <effectiveTime value="20241101"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e1b1b47f-8dfc-451c-9edd-9423d2a02471"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that if they have experienced hypersensitivity with other GnRH agonist drugs like LUTRATE DEPOT, LUTRATE DEPOT is contraindicated <content styleCode="italics">
                           <content styleCode="underline">[</content>see <linkHtml href="#_4_CONTRAINDICATIONS">Contraindications (4)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Tumor Flare</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that LUTRATE DEPOT can cause tumor flare during the first weeks of treatment. Inform patients that the increase in testosterone can cause an increase in urinary symptoms or pain. Advise patients to contact their healthcare provider if ureteral obstruction, spinal cord compression, paralysis, or new or worsened symptoms occur after beginning LUTRATE DEPOT treatment <content styleCode="italics">[</content>
                        <content styleCode="italics">s</content>
                        <content styleCode="italics">ee <linkHtml href="#_5_1_Tumor_Flare">Warnings and</linkHtml>
                           <linkHtml href="#_5_1_Tumor_Flare"> Precautions (5.1)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Metabolic Syndrome</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise patients that there is an increased risk of metabolic changes such as hyperglycemia, diabetes, hyperlipidemia, and non-alcoholic fatty liver disease with LUTRATE DEPOT therapy. Inform patients that periodic monitoring for metabolic changes is required when being treated with LUTRATE DEPOT <content styleCode="italics">[</content>
                        <content styleCode="italics">see <linkHtml href="#_5_2_Hyperglycemia_and">Warnings and Precautions (5.2)</linkHtml>
                        </content>
                        <content styleCode="italics">].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Cardiovascular Disease</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that there is an increased risk of myocardial infarction, sudden cardiac death, and stroke with LUTRATE DEPOT treatment. Advise patients to immediately report signs and symptoms associated with these events to their healthcare provider for evaluation <content styleCode="italics">[see <linkHtml href="#_5_3_Cardiovascular_Diseases">Warnings and Precautions (5.3)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Urogenital Disorders</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Advise patients that LUTRATE DEPOT may cause impotence <content styleCode="italics">[see <linkHtml href="#_8_3_Females_and">Use In Specific Populations (8.3)</linkHtml>]</content>.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Infertility</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that LUTRATE DEPOT may cause infertility <content styleCode="italics">[see <linkHtml href="#_8_3_Females_and">Use In Specific Populations (8.3</linkHtml>)].</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Continuation of LUTRATE DEPOT Treatment </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Inform patients that LUTRATE DEPOT is usually continued, often with additional medication, after the development of metastatic castration-resistant prostate cancer <content styleCode="italics">[see <linkHtml href="#L04648459-b708-4f1d-af99-a86ea0fe96b4">Dosage and Administration (2.1)</linkHtml>].</content>
                     </item>
                  </list>
                  <paragraph>Trademarks are property of their respective owners and are not of Avyxa Pharma, LLC</paragraph>
                  <paragraph>For more information on how to use, call 1-888-520-0954.Â </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for:</content>
                     <br/>Avyxa Pharma, LLC<br/>New Jersey 07054, USA<br/>
                     <br/>Made in Spain<br/>
                     <br/>99355081Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â </paragraph>
               </text>
               <effectiveTime value="20241101"/>
            </section>
         </component>
         <component>
            <section>
               <id root="2019d847-2aa0-4d2c-8202-fb81925f6b22"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDCÂ 83831-134-01 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lutrate<sup>Â®</sup> Depot<br/>(Leuprolide acetate for depot suspension)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">22.5 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For intramuscular injection</content>
                  </paragraph>
                  <paragraph>See package insert for reconstitution and administration procedures <br/> Recommended dose: one intramuscular injection every three months</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sterile <br/> Must be reconstituted before use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">AVYXA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ldc9ab6ac-d0e2-4488-9623-294515e785d7"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20241101"/>
               <component>
                  <observationMedia ID="Ldc9ab6ac-d0e2-4488-9623-294515e785d7">
                     <text>Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>